Inotrem is a biotechnology company focused on developing innovative immunotherapies that target the TREM-1 pathway, which plays a crucial role in regulating inflammatory responses. By modulating TREM-1, Inotrem aims to address both acute and chronic inflammatory diseases, including conditions such as septic shock and COVID-19. Their lead product, nangibotide, is currently in late-stage clinical trials, demonstrating the company's commitment to advancing treatments for severe inflammatory syndromes. Inotrem's approach is distinct from traditional inflammation inhibitors, as it seeks to restore a balanced immune response rather than simply suppressing it.

The company is also exploring a broad range of therapeutic modalities that leverage its proprietary technology platform, which is centered on the biology of TREM-1. This includes developing anti-TREM monoclonal antibodies to target chronic inflammatory diseases, as well as addressing critical care scenarios resulting from severe infections or major tissue injuries. Inotrem's focus on the TREM-1 pathway positions it uniquely in the field of immunotherapy, aiming to fulfill significant unmet medical needs in the treatment of inflammatory conditions.

France

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.

Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.

Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

Inotrem

Company Details